These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 17353550

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.
    J Clin Oncol; 2005 Feb 01; 23(4):667-75. PubMed ID: 15613697
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A.
    J Clin Oncol; 2006 Oct 20; 24(30):4867-74. PubMed ID: 17001068
    [Abstract] [Full Text] [Related]

  • 10. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.
    Cancer; 2005 Nov 15; 104(10):2141-8. PubMed ID: 16206291
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Nov 15; 115(2):215-20. PubMed ID: 19712963
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.
    J Clin Oncol; 2011 Sep 01; 29(25):3389-95. PubMed ID: 21810687
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
    Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J.
    Br J Haematol; 2005 Jun 01; 129(6):776-83. PubMed ID: 15953004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.
    Cancer; 2007 Sep 01; 110(5):1042-9. PubMed ID: 17654660
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.
    Ann Hematol; 2008 Aug 01; 87(8):623-31. PubMed ID: 18463870
    [Abstract] [Full Text] [Related]

  • 20. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
    Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK.
    Cancer; 2005 Apr 01; 103(7):1431-8. PubMed ID: 15739208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.